fenbendazole has been researched along with Ovarian Neoplasms in 3 studies
Fenbendazole: Antinematodal benzimidazole used in veterinary medicine.
fenbendazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted at positons 2 and 5 by (methoxycarbonyl)amino and phenylsulfanediyl groups, respectively. A broad-spectrum anthelmintic, it is used, particularly in veterinary medicine, for the treatment of nematodal infections.
Ovarian Neoplasms: Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We aimed to inhibit ovarian cancer (OC) development by interfering with microtubule polymerization and inhibiting mTOR signaling." | 1.91 | Anticancer Evaluation of Methoxy Poly(Ethylene Glycol)- ( Choi, JY; Lee, JW; Shin, DH; Shin, YB, 2023) |
| "Fenbendazole (FZ) has potential anti-cancer effects, but its poor water solubility limits its use for cancer therapy." | 1.91 | Anti-cancer effect of fenbendazole-incorporated PLGA nanoparticles in ovarian cancer. ( Chang, CS; Cho, YJ; Choi, JJ; Choi, JK; Choi, JY; Han, HD; Hwang, JR; Lee, CM; Lee, JW; Noh, JJ; Ryu, JY; Won, JE, 2023) |
| "Mebendazole was evaluated in cisplatin-resistant high grade serous stage 3C ovarian cancer patient derived xenograft (PDX) models: PDX-0003 (p53 null) and PDX-0030 (p53 positive), and on ovarian cancer cell lines: MES-OV (p53 R282W), ES2 (p53 S241F), A2780 (p53 wild type), SKOV3 parental (p53 null) and isogenic sublines, SKOV3 R273H p53 and SKOV3 R248W p53." | 1.62 | Potential and mechanism of mebendazole for treatment and maintenance of ovarian cancer. ( Benbrook, DM; Bieniasz, M; Elayapillai, S; Gunderson, CC; Hunsucker, LA; Isingizwe, ZR; Kennedy, AL; Lightfoot, S; Pathuri, G; Ramraj, S; Wang, L; Zhao, YD, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shin, YB | 1 |
| Choi, JY | 2 |
| Shin, DH | 1 |
| Lee, JW | 2 |
| Chang, CS | 1 |
| Ryu, JY | 1 |
| Choi, JK | 1 |
| Cho, YJ | 1 |
| Choi, JJ | 1 |
| Hwang, JR | 1 |
| Noh, JJ | 1 |
| Lee, CM | 1 |
| Won, JE | 1 |
| Han, HD | 1 |
| Elayapillai, S | 1 |
| Ramraj, S | 1 |
| Benbrook, DM | 1 |
| Bieniasz, M | 1 |
| Wang, L | 1 |
| Pathuri, G | 1 |
| Isingizwe, ZR | 1 |
| Kennedy, AL | 1 |
| Zhao, YD | 1 |
| Lightfoot, S | 1 |
| Hunsucker, LA | 1 |
| Gunderson, CC | 1 |
3 other studies available for fenbendazole and Ovarian Neoplasms
| Article | Year |
|---|---|
Anticancer Evaluation of Methoxy Poly(Ethylene Glycol)-
Topics: Cell Line, Tumor; Drug Carriers; Female; Fenbendazole; Humans; Micelles; Ovarian Neoplasms; Polyeste | 2023 |
Anti-cancer effect of fenbendazole-incorporated PLGA nanoparticles in ovarian cancer.
Topics: Animals; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Female; Fenbendazole; Humans; Mice; Nanopa | 2023 |
Potential and mechanism of mebendazole for treatment and maintenance of ovarian cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Repositioning; Drug | 2021 |